Therapy News and Research

RSS

Osiris second quarter revenues increase to $10.4 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the second quarter ended June 30, 2011.

5 Aug 2011

Metallofullerene platform holds promise for treatment of brain tumors

A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.

5 Aug 2011

Scientists identify small molecule inhibitors of cellular uptake

Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.

5 Aug 2011

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.

5 Aug 2011

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.

5 Aug 2011

Health Affairs report describes ground-breaking effort that aims to prevent opioid abuse

Fatal overdoses involving prescribed opioids tripled in the United States between 1999 and 2006, climbing to almost 14,000 deaths annually-more than cocaine and heroin overdoses combined. Hospitalizations and emergency room visits related to prescription opioid pain medicines such as oxycodone and hydrocodone also increased dramatically in the same period.

5 Aug 2011

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Akonni Biosystems, a molecular diagnostics company that develops novel nucleic acid extraction and microarray-based testing systems designed to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Health.

5 Aug 2011

News media registration now open for ASM annual infectious diseases meeting

News media registration for the annual infectious diseases meeting of the American Society for Microbiology (ASM) is now open.

5 Aug 2011

Scientists convert human skin cells into forebrain neurons

Columbia University Medical Center researchers have for the first time directly converted human skin cells into functional forebrain neurons, without the need for stem cells of any kind.

5 Aug 2011

PCF funds 10 new Challenge Awards for prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 10 new Challenge Awards for accelerating scientific discovery and new treatments for prostate cancer patients.

5 Aug 2011

Roadmap to overcome obstacles for using induced pluripotent stem cells

The possibility of developing stem cells from a patient's own skin and using them to treat conditions as diverse as Parkinson's disease, Alzheimer's disease and cancer has generated tremendous excitement in the stem cell research community in recent years. Such therapies would avoid the controversial need for using stem cells derived from human embryos, and in theory, also bypass immunological problems inherent in using cells from one person to treat another.

5 Aug 2011

Shear stress-based method can identify vulnerable plaque in coronary arteries

Researchers at Emory and Georgia Tech have developed a method for predicting which areas of the coronary arteries will develop more atherosclerotic plaque over time, based on intracoronary ultrasound and blood flow measurements.

5 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

Palatin confirms initiation of AZD2820 Phase 1 trial in obesity

Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.

4 Aug 2011

RNAi screen identifies Brd4 as a therapeutic target for acute myeloid leukemia

Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.

4 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.

From NanoString Technologies 4 Aug 2011

Positive results from hGH-CTP Phase II trial in growth hormone deficient adults

PROLOR Biotech, Inc. today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.

4 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

NIA, ACRO collaborate to create disease site-specific radiation oncology practice guidelines

National Imaging Associates (NIA), a subsidiary of Magellan Health Services, and the American College of Radiation Oncology (ACRO), the professional medical society established for educational and scientific purposes to advance the science and practice of radiation oncology, today announced the signing of a collaborative agreement.

4 Aug 2011